Hologenomix
Hologenomix · Why now

The tests are ready. The sample isn't

Reading got cheap, drugs target mutations, payers cover early detection. The blood draw still caps every test.

Scroll ↓

Reading got cheap. The sample stayed the same

$100M$100k$1002001201020202026DNA in one blood draw: ~6,000 copies$60Cost to read a genome

A genome: $100 million in 2001, $60 today. A blood draw: still ~6,000 copies.1

The best tests need the tumour. Screening has none

Without a tumour to learn from, screening tests stop near 1 in 1,000.2

August 2026

New drugs target the mutations a test reads

2×survival with the first RAS drug, 6.7 → 13.2 months
9 in 10pancreatic cancers driven by RAS
28 of 28patients' tumour DNA fell by half or more

Tumour DNA picks the patients and tracks the drug.3

February 2026

Medicare now pays to find cancer early

A new law covers FDA-approved multi-cancer screening tests.4

Every other route is smaller or manual

More tubes, bigger kits and lab concentration all fall short of a whole void in one step.5

More molecules

Others improve the test. We improve the sample.

Read the pitch →

[email protected]

Notes and sources

  1. A human genome cost about $100 million to read in 2001 and about $60 in 2026; a blood draw held ~6,000 genome copies then and holds ~6,000 now. Genome cost: NHGRI sequencing-cost data, approximate; the $60 genome is a sequencer maker's own figure (October 2026). Blood tests already choose the drug, watch for relapse and screen for bowel cancer: ~600,000 tests in Q3 2026 from the four largest US liquid-biopsy labs, up 70% on Q3 2025 (company reports). ↩
  2. The best relapse tests claim to see one tumour fragment in a million: they sequence the patient's tumour first, then track up to 5,000 of its mutations across the copies in the tube. Screening has no tumour to learn from, and screening tests stop at about 1 in 2,000 to 1 in 600. Company claims and FDA summaries, 2023–2026; NeXT Personal (Oncotarget 2024); PLoS One 2023. ↩
  3. The FDA approved the first RAS drug for pancreatic cancer on 26 August 2026: median survival 6.7 → 13.2 months in previously treated patients whose cancer has spread (phase 3, ASCO 2026, NEJM). RAS mutations drive about 9 in 10 of these cancers (KRAS ~93%, TCGA 2017). Doctors read tumour DNA to choose these drugs and to see if they work: in 28 of 28 patients it fell by half or more (ASCO Post, May 2026). The drug is now in trials right after surgery. ↩
  4. Public Law 119-75 (MCED Act, 3 February 2026) lets Medicare cover FDA-approved multi-cancer screening tests. Medicare already pays $1,495 for an FDA-approved blood screening test for bowel cancer and $3,500+ for a tumour-informed relapse test (CMS rates). Watching people at high risk pays off: about €14,000 per healthy year gained (Leiden CDKN2A surveillance programme, cost per QALY). ↩
  5. Draw more blood? Tests already take up to four tubes, about 24,000 copies against about 300,000 from one cup (FDA summary of an approved blood screening test). A bigger urine kit? Kits take 10–50 mL; a few products claim more, without convincing published data. Concentrate urine in the lab? It works: agreement with the tumour rose from 73% to 89% at 90–110 mL in 19 patients (Fujii et al., Clinical Cancer Research 2017, mixed advanced cancers), but as a manual lab protocol. Our device takes the whole void in one routine step. ↩